HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

<table>Overall survival of 14 patients with HIV-associated Burkitt lymphoma receiving CODOX-M/IVAC chemotherapy, 13 with HAART and 10 with rituximab.</table>

Advances in Hematology

fig1

Figure 1

Figure 1: HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era 

Figure 1 | HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era 